Singapore has sought out U.S. Covid-19 vaccine developer Arcturus Therapeutics Holdings Inc. and is funding its research in order to secure the first doses of any successful final product, in a reflection of the growing urgency in the race for immunization.
Daily Current Affairs Quiz 2020
Key-Points
As with many vaccine makers seeking a shot to control the pandemic, Arcturus has seen its stock soar. The shares have surged nearly 400% this year.
It’s too soon to know if Arcturus’s vaccine will be effective, and Payne didn’t give a time frame for when it could reach the market.
The vaccine, known as Lunar-Cov19, is one of approximately 20 candidates globally that have reached the clinical trial phase.
Singapore’s Health Sciences Authority granted approval in July for the vaccine to be tested in a study involving 108 healthy volunteers of varying ages.
More than 160 vaccines are currently under development globally. Moderna Inc. and China’s CanSino Biologics Inc. are among the leading candidates with shots in the advanced stages of human testing.
